JPMorgan Chase & Co. Has $12.67 Million Position in Cellebrite DI Ltd. $CLBT

JPMorgan Chase & Co. lessened its position in Cellebrite DI Ltd. (NASDAQ:CLBT) by 21.2% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 683,842 shares of the company’s stock after selling 183,531 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.29% of Cellebrite DI worth $12,672,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of CLBT. Cooper Creek Partners Management LLC acquired a new position in Cellebrite DI during the 3rd quarter worth approximately $55,999,000. Granahan Investment Management LLC raised its holdings in shares of Cellebrite DI by 1,108.5% in the third quarter. Granahan Investment Management LLC now owns 2,629,299 shares of the company’s stock valued at $48,721,000 after purchasing an additional 2,411,726 shares during the last quarter. Invesco Ltd. lifted its position in shares of Cellebrite DI by 58.6% in the third quarter. Invesco Ltd. now owns 5,560,196 shares of the company’s stock worth $103,030,000 after purchasing an additional 2,054,644 shares in the last quarter. Pertento Partners LLP lifted its position in shares of Cellebrite DI by 57.8% in the third quarter. Pertento Partners LLP now owns 4,648,215 shares of the company’s stock worth $86,131,000 after purchasing an additional 1,702,574 shares in the last quarter. Finally, Portolan Capital Management LLC boosted its holdings in Cellebrite DI by 139.1% during the third quarter. Portolan Capital Management LLC now owns 2,419,662 shares of the company’s stock worth $44,836,000 after purchasing an additional 1,407,818 shares during the last quarter. Institutional investors own 45.88% of the company’s stock.

Cellebrite DI Trading Down 6.1%

NASDAQ:CLBT opened at $12.95 on Friday. Cellebrite DI Ltd. has a 1-year low of $11.76 and a 1-year high of $20.53. The firm has a fifty day simple moving average of $14.52 and a 200 day simple moving average of $16.75. The stock has a market capitalization of $3.23 billion, a PE ratio of 41.77, a P/E/G ratio of 2.11 and a beta of 1.30.

Cellebrite DI (NASDAQ:CLBT) last issued its earnings results on Wednesday, February 11th. The company reported $0.14 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.14. The business had revenue of $128.82 million for the quarter, compared to the consensus estimate of $126.07 million. Cellebrite DI had a net margin of 16.47% and a return on equity of 20.43%. The firm’s revenue for the quarter was up 28.8% on a year-over-year basis. During the same period in the previous year, the company earned $0.10 earnings per share. On average, equities analysts predict that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on CLBT shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cellebrite DI in a research report on Monday, December 29th. Wall Street Zen upgraded shares of Cellebrite DI from a “sell” rating to a “hold” rating in a research note on Sunday, March 15th. Finally, Needham & Company LLC decreased their price objective on Cellebrite DI from $24.00 to $18.00 and set a “buy” rating for the company in a report on Thursday, February 12th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $22.50.

Cellebrite DI Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.